American Society of Hematology

SHERPA: Blue

People

  1. Giralt
    Giralt
  2. Zelenetz
    Zelenetz
  3. Levine
    Levine
  4. Tallman
    Tallman
  5. Perales
    Perales
  6. O'Reilly
    O'Reilly
  7. Horwitz
    Horwitz
  8. Devlin
    Devlin
  9. Kernan
    Kernan
  10. Abdel-Wahab
    Abdel-Wahab

Groups

  1. Department of Medicine (3844)
  2. Hematologic Malignancies, Division of (3639)
  3. Center for Hematologic Malignancies (3542)
  4. GSK Faculty (1553)
  5. Adult Leukemia (1289)
  6. Sloan Kettering Institute Faculty (1065)
  7. Bone Marrow Transplant (936)
  8. Center for Molecular Imaging and Biotechnology (CMIB) (931)
  9. Lymphoma (898)
  10. Tow Center for Developmental Oncology (TCDO) (863)
Search Within
Formats
  1. Meeting Abstract (3939)
  2. Journal Article (1239)
  3. Research Letter (44)
  4. Review (44)
  5. Editorial (34)
  6. Guidelines (13)
  7. Correspondence (7)
  8. Miscellaneous (3)
Groups
  1. Department of Medicine (3844)
  2. Hematologic Malignancies, Division of (3639)
  3. Center for Hematologic Malignancies (3542)
  4. GSK Faculty (1553)
  5. Adult Leukemia (1289)
  6. Sloan Kettering Institute Faculty (1065)

More Groups

People
  1. Sergio Giralt (337)
  2. Andrew Zelenetz (328)
  3. Ross Levine (312)
  4. Martin Tallman (298)
  5. Miguel-Angel Perales (292)
  6. Richard O'Reilly (281)

More People

Years
  1. 2025 (43)
  2. 2024 (217)
  3. 2023 (478)
  4. 2022 (369)
  5. 2021 (284)
  6. 2020 (261)

More Years

Publications
  1. Blood (4951)
  2. Blood Advances (322)
  3. Hematology-American Society of Hematology Education Program (50)

Results (5323)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase 1/2 study of nuvisertib (TP-3654), an investigational selective PIM1 kinase inhibitor, in combination with JAK inhibitors ruxolitinib or momelotinib in patients with myelofibrosis
    Meeting Abstract

    Mascarenhas, J. O.; Rampal, R.; El Chaer, F.; Gupta, V.; Shimoda, K.; Kiladjian, J. J.; Passamonti, F.; Bose, P.; Scandura, J. M.; Mesa, R.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • US expert consensus on defining intolerance to tyrosine kinase inhibitor treatment in chronic phase chronic myeloid leukemia (CML)
    Meeting Abstract

    Atallah, E. L.; Broder, M. S.; Chan, O.; Dalglish, H.; Flynn, K. E.; Gilreath, J.; Hine, M.; Hunter, A. M.; Mauro, M. J.; Pinilla-Ibarz, J.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Real-world (RW) outcomes for brexucabtagene autoleucel (Brexu-Cel) treatment in patients (Pts) with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) by high-risk features and prior treatments: Updated evidence from the CIBMTR® registry
    Meeting Abstract

    Wudhikarn, K.; Bezerra, E.; Yang, Y.; Perales, M. A.; Jain, N.; Gergis, U.; Aribi, A.; Hill, L.; Leonard, J. T.; Lutfi, F.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Impact of novel therapies (NTs) on real-world (RW) clinical outcomes of patients (pts) with relapsed/refractory (RR) mantle-cell lymphoma (MCL) by race/ethnicity and TP53 mutation status
    Meeting Abstract

    Phillips, T. J.; Danilov, A. V.; Ruan, J.; Patel, K.; Kumar, A.; Wang, Y. C.; Maglinte, G. A.; Seymour, E.; Kamdar, M.
    Blood (2024)

    Fulltext@MSK | Save
  • Impact of the diagnosis-to-treatment interval (DTI) on outcomes in older adults with diffuse large B-cell lymphoma (DLBCL) treated in the real-world setting
    Meeting Abstract

    Hamlin, P. A.; Torka, P.; Hansen, E.; Belli, A. J.; Ambrose, J.; Zettler, C. M.; Fernandes, L. L.; Wiley, S.; Perry, B.; Wang, C. K.
    Blood (2024)

    Fulltext@MSK | Save
  • Trials in progress: The START (STrategies for Anticoagulation in patients with thRombocytopenia and cancer-associated Thrombosis) pilot randomized controlled trial
    Meeting Abstract

    Wang, T. F.; Thomas, M.; Leader, A.; Cervi, A. L.; Wu, C. M.; Stanworth, S. J.; Carrier, M.
    Blood (2024)

    Fulltext@MSK | Save
  • A niche driven mechanism determines response to ATRA and a mutation-independent therapeutic approach for MDS and AML
    Meeting Abstract

    Mosialou, I.; Ali, A. M.; Cuesta-Dominguez, A.; Labella, R.; Vgenopoulou, V.; Bisikirska, B.; Galan-Diez, M.; Wang, A. Q.; Bewersdorf, J. P.; Liang, C.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Risk factors associated with sub-optimal outcomes following obecabtagene autoleucel (obe-cel) for relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL): What we have learned from the FELIX trial
    Meeting Abstract

    Roddie, C.; Park, J. H.; Shaughnessy, P.; Logan, A. C.; Sandhu, K. S.; Abedi, M.; Shah, B. D.; Bishop, M. R.; DeAngelo, D. J.; Brugger, W.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Manufacture of anti-BCMA CAR T cell is feasible after salvage autologous or allogeneic hematopoietic stem cell transplantation
    Meeting Abstract

    Shah, G. L.; Perica, K.; Nagel, K.; Payson, E.; Hosszu, K. K.; Chung, D. J.; Landau, H. J.; Scordo, M.; Hultcrantz, M.; Korde, N.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • An open-label, multi-center phase 2 study to assess the safety and efficacy of burixafor (GPC-100) and propranolol with G-CSF for the mobilization of stem cells in patients with multiple myeloma undergoing autologous stem cell transplant
    Meeting Abstract

    Caculitan, N.; Kim, G.; Woolfrey, A.; Akard, L. P.; Jeong, A. R.; Khouri, J.; Shah, G. L.; Cardarelli, P. M.
    Blood (2024)

    Fulltext@MSK | Save